Background and purpose: Adults with compromised liver function are inherently deficient and especially vulnerable to the consequences of vitamin D deficiency. Consequences of vitamin D deficiency include liver disease progression, infection, and graft failure. A vitamin D supplementation protocol is proposed to systematically optimize serum vitamin D levels according to guidelines in both pre-and post-liver transplanted patients. Methods: This quasiexperimental study included a sample of N = 45 postliver transplanted patients taking daily cholecalciferol (vitamin D3) 2500 units for 12 weeks, with a pre-and post-lab measure of serum 25-hydroxyvitamin D levels at a large academic facility. Conclusions: Seventy-eight percent of patients reached minimum guideline levels using the protocol with an average increase of serum vitamin D of 13.8 ng/mL. Long-term outcomes of clinical significance may include decreased incidence of acute T-cell-mediated graft rejection and infections in the immunocompromised patient. Implications for practice: Optimizing vitamin D in vulnerable patient populations such as chronic liver disease and the immunosuppressed posttransplanted patient has the potential to curtail complications of vitamin D deficiency. As a result, nurse practitioners employing a vitamin D protocol can create a favorable impact on patient quality of life, safety, and healthcare spending.
Introduction
Vitamin D deficiency (VDD) is endemic among patients with end-stage liver disease listed for transplantation (Abu-Mouch, Fireman, Jarchovsky, Zeina, & Assy, 2011; Chaney, Heckman, Diehl, Meek, & Keaveny, 2015; Stein & Shane, 2011; Zhang et al., 2016) . This deficiency has been reported to be as high as 91% (Chaney et al., 2015; Choudhary et al., 2011) . Vitamin D (VD) has a number of pleiotropic effects including anti-inflammatory properties; antiapoptosis; antifibrosis; regulation of function in the kidney, heart, and immune system; and it maintains homeostasis by regulation of hormone secretion, cell proliferation, and differentiation (Lai & Fang, 2013) . Research outlines the merits of VD supplementation (VDS) in patients with chronic liver disease (CLD) of various etiologies (Anty et al., 2014; DiCarlo et al., 2015; Eliades & Spyrou, 2015; Fernandez-Fernandez, Linares-Torres, Matias, Jorquera-Plaza, & Olcoz-Goni, 2015) . Cited benefits can be stratified into areas such as the immune system (innate and adaptive), bone health, and all-cause mortality (Iruzubieta, Teran, Crespo, & Fabrega, 2014; Stokes, Volmer, Grunhage, & Lammert, 2013; Villar, Del Campo, Ranchal, Lampe, & Romero-Gomez, 2013) .
Background and local context
The model for end-stage liver disease, or MELD, is a scoring system that determines listing priority for transplantation with 40 points being the maximum. It is composed of four different lab values: creatinine, international normalized ratio (INR), total bilirubin, and, in 2016, sodium was added. Worsening lab values will increase a patient's MELD score, moving them to a higher position on the list. Other factors that can supplement the score include hepatocellular carcinoma (HCC) and dialysis. There are considerable geographic disparities in organ availability in the United States. Southern California is part of a region with the highest average MELD score needed for transplant at 33, whereas regions in the Midwest have average scores of 25 (Frenette et al., 2015) .
Patients listed for liver transplantation at the author's facility have an average MELD score of over 35 at time of transplantation. At such high MELD scores, patients are very ill and often tenuous. Nutrition is paramount to supportive care and many micronutrient deficiencies are noted in this population. VDD is rampant and can persist long after transplantation (Courbebaisse et al., 2014; Thiem, Olbramski, & Borchhardt, 2013) . Immune system compromise, hyperparathyroidism, bone loss, fracture, muscle weakness, falls, hypertension, and malignancy have all been associated with VDD (Stein et al., 2009) . In patients with cirrhosis, the incidence of VDD (<25 ng/mL) increases with worsening synthetic liver dysfunction (Kitson & Roberts, 2012; Zhang et al., 2016) . With respect to patient safety, therapeutic VD levels have been shown to increase strength (Bischoff-Ferrari et al., 2004 , and although it has not shown to reduce falls in the VD-optimized population, it is thought to have an effect on muscle strength in those that are severely deficient (Gillespie et al., 2012) . By implementing a VDS protocol, the goal is to reach and sustain the minimum VD level of 30 ng/mL as recommended by the Endocrine Society, The American Association for the Study of Liver Diseases, and The American Society for Transplantation (Holick et al., 2011; Lucey et al., 2013) . VDS using ergocalciferol (vitamin D2) was the approach at the study site among liver transplant providers. The move towards cholecalciferol (vitamin D3) was desirable given the evidence that showed longer periods of sustained VD serum levels than the alternative form, vitamin D2 (Logan, Gray, Peddie, Harper, & Houghton, 2013; Mangoo-Karim et al., 2015; Osborn & Germann, 2011) .
Successful optimization of serum 25(OH)D levels of patients to 40 ng/mL has the potential to reduce the overall direct economic strain of disease by 11.4%, or $118 million and would decrease the indirect economic impact of disease by $93 million (Grant et al., 2009) . In turn, this would result in a comprehensive reduction in economic burden of disease by 17.7%, or $211 million (Grant et al., 2009) .
Although studies have highlighted numerous benefits that VDS would confer in CLD and the posttransplant population, few venture to recommend standardizing a protocol that would assure therapeutic levels. The primary purpose of this study was to employ a vitamin D3 dosing protocol (Figure 1 ) developed from the input of a multidisciplinary team and subsequently assess serum C. Grant levels for the protocol dose effectiveness in patients postliver transplantation in an effort to meet recommended guidelines in this population. Although both pre-and posttransplanted patients receive supplementation at the study site, this project focused only on the posttransplanted patients' response to this dosing schedule. This protocol replaces the previously used vitamin D2 at the author's facility.
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Clinical practice guidelines on VDS
The American Association for the Study of Liver Diseases (AASLD) is a predominant voice in the United States for opinion in the field of liver disease, and providers in hepatology and related practice areas refer to AASLD for guidance on treatment for liver-related subject matter. The AASLD, together with the American Society of Transplantation, publishes clinical practice guidelines (CPG) for successful long-term management of the adult liver transplant recipient. In the guidelines, the benefits from VDS in the posttransplanted patient are addressed and include improved sustained virologic response for patients with hepatitis C (HCV), immune system fortification against both infection and graft rejection, and a decreased incidence of malignancies (Lucey et al., 2013) . Moreover, these organizations along with the Endocrine Society recommended maintaining a minimum of 30 ng/mL serum VD (Holick et al., 2011) . Additionally, patients on steroids, antifungals, and antiviral medications used for prevention of hepatitis B recurrence are also at a higher risk for VDD and should be supplemented two to three times more than their age group requires (Holick et al., 2011) .
VD and the immune system
Adaptive versus innate immunity. The role of VD in calcium regulation and bone homeostasis is well established (Holick et al., 2011; Lucey et al., 2013) ; however, VD has also been recognized as possessing immunomodulatory, anti-inflammatory, and antifibrotic properties (Arteh, Narra, & Nair, 2010; Fernandez-Fernandez et al., 2015; Kitson & Roberts, 2012) . Additionally, VD has a key function in the management of cell proliferation and differentiation, both being extra-skeletal effects that are important in the pathogenesis and treatment of various etiologies of liver disease (Kitson & Roberts, 2012) . With respect to adaptive immunity, VD is an essential regulator of T-cell response (upregulation) to pathogens, and VDS is associated with a lower risk of autoimmune diseases such as primary sclerosing cholangitis and autoimmune hepatitis (Kitson & Roberts, 2012; Putz-Bankuti et al., 2012) . In liver transplant recipients, severe VDD has been associated with moderate to severe acute T-cell-mediated rejection (ATCR) with VDS decreasing the incidence of ATCR by as much as 60% (Kitson & Roberts, 2012; Stein & Shane, 2011; Thiem et al., 2013) . Reducing graft failure is a highly desirable outcome of VDS as ATCR can predispose a patient to steroid-resistant rejection and graft loss (Cotler, 2016) .
VDS has also been shown to increase the effectivity of the innate immune system, thus providing protection against bacterial infections and tuberculosis (Anty et al., 2014; Chowdhury et al., 2014; Putz-Bankuti et al., 2012; Stein & Shane, 2011; Zhang et al., 2016) . Notably, cirrhotic patients with severe VDD (<10 ng/mL) were independently associated with bacterial infections compared to patients with higher VD levels (Anty et al., 2014; Zhang et al., 2016) , and low VD prior to hospitalization was a significant predictor (p = .001) of sepsis in the critically ill (Moromizato et al., 2014) .
Sustained virologic response.
Chronic HCV is one of the main causes of liver disease and increases the risk of developing HCC by 2-6% per year (Oliviera-Andrade et al., 2009). Recent in vitro studies have shown that VD acts as an antiviral agent that inhibits HCV production in a human hepatoma cell line (DiCarlo et al., 2015) . In patients with HCV that underwent liver transplantation with subsequent recurrent HCV, high rates of sustained virologic response were noted in patients receiving VDS (AbuMouch et al., 2011; Bitetto et al., 2011; Iruzubieta et al., 2014) . Additionally, VD facilitates zinc uptake, which is considered to be a negative regulator of HCV replication (Elangovan, Chahal, & Gunton, 2017) .
Cancer. The association of VDD and cancer development is prevalent in the literature, namely colon, prostate, and breast cancer (Iruzubieta et al., 2014; Stein et al., 2009; Stokes et al., 2014; Villar et al., 2013) . VDD is widespread among cancer patients with one study showing 74% of breast cancer patients to be low in VD and VDS conferring a 15% decrease in mortality among lung cancer patients (Aguirre et al., 2016) . Relevant to liver disease, hepatocellular and intrahepatic cholangiocarcinoma often develop in patients with cirrhosis and is inversely related to levels of VD (Stokes et al., 2013) . VD is associated with promotion of antiapoptotic activity, as well as anti-inflammatory and antiangiogenic properties that contribute to cell differentiation and inhibit cancer cell proliferation (Courbebaisse et al., 2014; Elangovan et al., 2017; Stokes et al., 2013) .
VD and hepatic osteodystrophy
Bone loss associated with liver disease and related treatment is of considerable concern and the subject of studies, reviews, and CPG. Also known as hepatic osteodystrophy (HO), this general term defines a group of derangements of bone mineral metabolism found in patients with CLD (Lopez-Larramona, Lucendo, Gonzalez-Castillo, & Tenias, 2011) . Bone loss in this population can be severe enough to cause atraumatic fractures, leading to compromised mobility and subsequent decrease in quality of life (Nakchbandi, 2014) . However, HO is multifactorial in origin and appears to be the consequence of metabolic bone disease making it impossible to process VD because of the interruption in liver function from disease (Choudhary et al., 2011; Lopez-Larramona et al., 2011; Nakchbandi, 2014) . Although research has been inconsistent with respect to effect of VDS and HO, a meta-analysis examining the association between VDS and fracture concluded that a somewhat favorable reduction in the prevention of hip and nonvertebral fractures in people age 65 and older (Bischoff-Ferrari et al., 2012) was appreciated.
VD and mortality in liver disease
In 2013, CLD was ranked 12th in the leading causes of death in the United States and fifth in Europe (Xu, Murphy, Kochanek, & Bastian, 2016) . VDD has been associated with higher mortality risk in the general population, and patients with CLD are extremely vulnerable to the consequences of VDD as well (Stokes et al., 2014) . Furthermore, a large observational study conducted by the U.S. National Health and Nutrition Examination Survey (NHANES) concluded that serum VD levels are inversely related to all-cause mortality (Zhao, Ford, Li, & Croft, 2012) . In a meta-analysis of 18 randomized controlled trials, Autier and Gandini (2007) concluded that VDS correlated with a reduction in overall mortality in the general population.
The case for VDS
A recent resurgence of the benefits of VD on overall health of the general population contributed to a meta-analysis of 25 randomized, placebo-controlled trials evaluating the dose-response relationship of vitamin D3 (Jarrett, Ducasa, Buller, & Berwick, 2014) . A regression analysis of all reviewed studies showed a correlation of 61%, which supported a consistent dose-response relationship independent of various confounders (Jarrett et al., 2014) . Additionally, the researchers found that healthy and ill individuals did not vary on response to dose, supporting a generalizable dosing schedule (Jarrett et al., 2014) . In a meta-analysis of randomized controlled trials of VDS, it was found that high-dose VDS (ࣙ800 IU/day) was more beneficial in the prevention of hip fracture and any nonvertebral fracture in people 65 years and older (Bischoff-Ferrari et al., 2012) . Long-term studies on the impact of VDS on nonskeletal systems are sparse and many articles cite this as an essential component to advancing knowledge regarding the benefits of VDS (Manson & Bassuk, 2015) .
Research design and methodology
The evaluation of this protocol on patients who underwent liver transplantation within the last 3 years was a quasiexperimental study. Given that this protocol is a replacement for an existing intervention to VDS, the use of implementation theory was employed. Cronenwett, Sherwood, Pohl, Barnsteiner, and Moore (2009) argued that advanced practice nurses must be competent in the principles of change management. Rogers' Diffusion of Innovations (DOI) theory is one method that facilitates change and promotes translation of CPG to daily practice. Health care has a long history of examining what works and why, but too often it fails to completely implement those findings (MacDonald, Graham, & Grimshaw, 2004) . Through the use of theories aimed at implementing evidence, such as CPG into systems, root causes can be addressed by promoting studied evidence and examining how the stakeholders will best accept and utilize this information.
Participants and setting
An application was filed with the Institutional Review Board at the study site UCLA Medical Center who deemed this observational study as exempt from review. The setting was an academic tertiary hospital and the corresponding outpatient hepatology clinics in Los Angeles, California. Subjects were post-liver transplantation of 3 years or less with normal renal function as defined by a glomerular filtration rate of >30, found to be VDD as defined by a serum 25-OH D level of less than 30 ng/mL. Details on participant characteristics are found in Table 1 . Over half of the participants were Hispanic with similar incidence of hepatitis C and alcoholic-induced cirrhosis. The study demographic breakdown unintentionally mirrored the city's demographics as reported in the 2010 U.S. census ("U.S. Census," 2016). The gender distribution was nearly equal.
The inpatient census on the liver transplant service was reviewed for eligible participants as well as the outpatient hepatology clinic schedule on a weekly basis. Preintervention serum 25-OH hydroxy levels were assessed and if they were found to be <30 ng/mL, the patients started the vitamin D3 supplementation protocol and repeat VD levels were reviewed at 12 weeks.
The primary outcome was to assess the effectiveness of the proposed vitamin D3 protocol on serum levels. The Note. NASH, nonalcoholic steatohepatitis.
baseline VD level was compared to the 12-week VD level. Secondary outcomes included evaluating the dose in the patients that were not successfully optimized to 30 ng/mL. Patients with lower VD levels may need a more aggressive supplementation protocol, rather than the homogeneous dosing schedule used in this protocol.
Data collection procedure
Eligible patients were approached and educated on the importance of VDS by the author. If the patient was not currently taking VD, vitamin D3 2500 IU/day was added to the medication list for a duration of 12 weeks and the start date was noted in the author's database. To capture additional subjects, the author approached the director of posttransplant coordination who then facilitated a weekly outpatient hepatology clinic list with patient names and transplant dates. Approximately 60 patient charts were reviewed every week over the course of 4 months that resulted in over 900 charts reviewed for the time period.
Additional patients were identified on a weekly basis until January 2017. After the 12-week course of D3, patients returned to clinic for their regularly scheduled hepatology appointment and a VD level was obtained. This result was compared to the pretreatment VD level.
The primary outcome measure was the difference between the pre-and posttreatment serum levels of 25(OH)D. Recruitment continued until the 12-week treatment duration would place the patient's redraw date beyond March 2017. The first patients were captured in September 2016 with the last added in January 2017. With these criteria, a total of 48 subjects were added. However, one patient's endocrinologist changed him to D2, and two patients declined to pay the supplemental cost for the D3. Adjusting for these cases, total number of patients reviewed numbered 45.
Data analysis
The lab data collected during the study were entered into and analyzed using SPSS version 23 (SPSS Inc., Chicago, IL). A pair sample t-test was used to compare the mean change between the pre-and postserum 25-OH hydroxy. Additional analysis examined dose response with respect to CLD etiology, race, and gender.
Results
Before patient recruitment began, the author met with statisticians and discussed an appropriate sample size. It was hypothesized that approximately 70% of the patients would respond to the dose indicated by endocrinology and reach the minimum target level of 30 ng/mL as found in the meta-analysis by Jarrett et al. (2014) and Pilz et al. (2016) . Based on this expectation a power analysis was calculated to determine appropriate sample size that would give a confidence interval (CI) of >90%. Final data indicated that 35 of the 45 patients reached the minimum VD serum level of 30 after VDS, or 78% of the subjects. This Figure 2 The response to vitamin D supplementation by etiology. ETOH, alcoholic cirrhosis; HCV, hepatitis C cirrhosis; NASH, nonalcoholic steatohepatitis. Other includes autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, polycystic liver disease, and hepatitis B cirrhosis. was a greater than expected response. Additionally, there was a mean change in serum VD level of 14 ng/mL; however, not all of the patients in the study reached the minimum level of 30 ng/mL.
Additional analysis was performed on the following subcategories of the study subjects: etiology of liver failure illustrated in Figure 2 , demographics (Figure 3) , and gender (Figure 4 ). There were some significant differences in how these subcategories responded, namely, Asians had an average increase of over 80% postintervention. Females also appreciably improved postintervention at 81%, while males had a 62% change postintervention. There were no significant differences in improvement among the varying etiologies of liver failure.
An estimate of the proportion of responders to the VD intervention, along with a 95% CI, was reported. A onesided one-proportion z-test was used to evaluate the null hypothesis that 50% or fewer will respond after the VD intervention. A p-value less than .05 was considered statistically significant. The sample size of N = 45 provides 94% power to detect a true proportion responding after the VD intervention of 78% (p < .001).
Discussion
This quality improvement research project raised awareness of the importance of VD in this vulnerable population. Accordingly, co-workers and transplant coordinators were more vigilant with this lab value and benefits to VDS than prior to the project. The VDS protocol was shown to be an effective approach to optimizing serum levels and a large portion of the patients that were started on D3 reached the minimum dose as recommended by the guidelines. The project's success relied heavily on the team approach to facilitating the protocol implementation. Although the author was the primary agent following the patients and their redraw dates, at many points in time the posttransplant coordinators were contacted regarding details about the patients' access to VD as well as their expected return to clinic. Additionally, the transplant pharmacist was exceedingly helpful and cooperative in sending the supplementation to patients' homes in the event that they were not expected back in clinic within 1-2 weeks.
Comparing dose-response results with published literature was a challenge because there are limited studies dedicated to VDS in liver disease and posttransplant. However, as Jarret et al. (2014) observed in their meta-analysis of 36 studies, the dose response of VDS did not vary in the absence of chronic disease. Both healthy and chronically ill populations that were analyzed responded well to VDS. The results from this study were compared to the meta-analysis by Jarrett et al. (2014) as well as a randomized controlled trial by Pilz et al. (2016) examining VDS, specifically in cirrhotic patients.
In their meta-analysis, Jarrett et al. (2014) plotted the data from 20 of the most reliable and homogeneous studies on a scatter plot, which showed a positive correlation between the quantity of oral VD and the change in serum levels. Based on this information, a daily dose of D3 at 2500 units would produce a change in serum level of 16 ng/mL. In the randomized controlled trial (RCT) of cirrhotic patients, Pilz et al. (2016) employed a daily dose of 2800 units/day and found a mean change from baseline post VDS of 18 ng/mL. The mean change among the author's study subjects was 14 ng/mL with the 2500 unit daily dose that resembles the meta-analysis and the RCT findings. Although both studies discussed a minimum normal range of 30 ng/mL, the number of patients that reached that goal post VDS was only reported in ranges rather than in individual cases.
Limitations
There are some limitations that should be mentioned with respect to the results. This was a single-center observational study with a small sample size. There are no previous studies, to the author's knowledge, that examine posttransplant VDS and dose response. In newly transplanted patients, the exact effect of the functioning liver on the improvement of serum VD is unclear. However, liver disease does not always impair VD receptor function and hypovitaminosis D is thought to be a consequence largely in part to poor nutritional intake and sedentary lifestyle (Elangovan et al., 2017) .
Conclusions
This simple, inexpensive intervention has the potential for a high yield on investment based on the evidence of the protective benefits of VDS in the liver failure and transplanted population. Some of the important effects of optimized VD levels can have posttransplantation include the decreased incidence of acute cellular rejection, decreased rate of infection, and reduced incidence of fracture (Kitson & Roberts, 2012; Moromizato et al., 2014; Nakchbandi, 2014) . The rationale for this center's transition from vitamin D2 to vitamin D3 is none other than supporting evidence promoting the duration of effect for D3 over D2 (Logan et al., 2013; Mangoo-Karim et al., 2015; Osborn & Germann, 2011) . Cost differences between the two forms of VD are minor, however, some insurance policies will cover vitamin D2 and require patients to pay out of pocket for D3 (approximately $12 for a 12-week course). Vitamin D2 is an acceptable approach to optimizing serum levels, and this is still used for patients not on D3.
Given the limited time frame for which to evaluate the effects of long-term optimized VD, further studies will be needed to determine if the VDS and subsequent optimization of serum 25(OH)D can curtail the incidence of graft rejection, infection, fractures, and other consequences of VDD. Tracking newly liver-transplanted patients that are maintained with VDS and their incidence of graft failure in comparison, retrospectively, with patients who were noted to be consistently VDD is one example of how VDS can be confirmed as an essential component of treatment in this population.
Implications for practice
VDS has been shown to have a positive effect for the immunosuppressed patient both before and after liver transplantation. Implementing a VD protocol is well within the scope of practice for nurse practitioners (NPs) and has the potential to yield many benefits to this vulnerable population. CPG are based on evidence found through quality studies but it is not enough to publish these guidelines. Adhering to recommendations of expert organizations is an effective way to utilize evidence-based practice, one of the core competencies of an advanced practice nurse (Cronenwett et al., 2009 ). Today's NPs can be these change agents and facilitate this translation of data into practice.
